FEMY

Femasys Inc. (FEMY) | Rumor.io

Femasys

FEMY

Attention (50-day avg)0.01%

Attention rank (50-day avg)#602

Bullish sentiment (50-day avg)84%

Price to earnings ratio-0.25

Market capitalization19.9M

Earnings per share-2.72

Dividend yield (TTM)—

Revenue (annual)2.3M

Net income (annual)-18.6M

Social

What share of all stock conversation is about FEMY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% -0.01	0% 0

Aug 28

Femasys Inc. (FEMY) has partnered with UNC, and its undervalued market capitalization can support a price of $10+.
The company's regulatory milestone for its investigational birth control technology has led to a stock rally, with potential for 500% upside.
FEMY's low volume and price movement are notable, despite the market's fickle nature and potential for further dips or a significant run.

Generated by AI

Sentiment

Of the messages about FEMY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	85.71% +2.11	85.62% -3
Bearish	—	100% new	14.29% -2.11	14.38% +3

Bullish· Aug 19

FEMY has secured $30M in institutional financing, which has taken a significant strategic position in the company, and has also received millions of warrants with strikes at $2.95.
FEMY has made significant progress with the FDA, agreeing to a modular PMA pathway for FemBloc, and has already received approval for marketing in Europe and select international markets.
FEMY's recent news and financing in place have attracted key institutional investors, including Nantahala Capital, which has invested ~$12M at $3.20/share, and received millions of warrants.

Bearish· Aug 19

The company's FDA approval news may not lead to immediate financial improvement and could be used for pump and dump campaigns.
Many investors are expecting a significant price drop, with some predicting a 30% decline from the current level.
The asset is considered a "piece of trash" and "diarrhea" by some investors, with one predicting it will go to $2.86 and another stating it will be a 100% loss.

Generated by AI

Topics

Of the messages about FEMY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	16.56%
Technical Analysis	—	—	0%	17.22%
Analysts	—	—	0%	31.96%
Macro	—	—	0%	29.57%
Controversies	—	—	0%	0%
Earnings	—	—	0%	4.69%

Earnings· Nov 16

FEMY fell despite beating estimates, potentially due to unclear EPS release date and low trading volume.
DFLI, another stock that missed estimates, surged instead, possibly due to its own characteristics and lower short interest.
FEMY and DFLI are both being suppressed by significant short interest and have not yet achieved full profitability.

Announcements· Nov 7

Femasys Inc. (FEMY) has filed an 8-K announcing a $12 million private placement of senior secured convertible notes and warrants.
The private placement includes personal investments by the CEO, CFO, and a board member, indicating their confidence in the company's growth prospects.
The funds raised will be used to pay off previous debt and fund operations, with the lead investor taking a board seat to signal long-term commitment and support for the company's expansion plans.

Technical Analysis· Oct 17

$FEMY is in a consolidation phase just below its 21-day EMA and needs to break above 1.65 to start a new momentum.
The stock has been trending sideways, with STO/RSI momentum oscillators twitching just above the oversold zone, and has a potential reversal signal due to its accumulation level.
$FEMY has formed a bullish deep bat formation from 1.31, indicating a strong buy signal, and has broken out of a down-trending channel, with a potential gap up above 1.55-1.60.

Generated by AI

Community

Of the messages about FEMY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	63.64%	37.34%
Newcomers	0%	0%	36.36%	62.66%

Regulars· Aug 19

Femasys has received $30M in institutional financing, with Nantahala taking a significant strategic position, and the FDA agreeing to a modular PMA pathway for FemBloc, potentially shortening the time to approval.
The FDA's agreement to a modular PMA pathway is a positive signal, and Femasys already has FemBloc approved for marketing in Europe and select international markets.
Femasys has the potential to become a non-surgical alternative to hysterectomies, with FemBloc already approved in Europe and New Zealand, and the company has a significant amount of cash on hand.

Newcomers· Aug 19

The newcomers are primarily focused on the potential for FEMY to increase in value, with some predicting it will reach $4 today and others anticipating a significant surge in value, potentially reaching $10-20 billion.
The newcomers are also focused on the potential for FEMY to break out above $3.15, with some already buying in at $3.00 and others expecting a rapid increase in value if it breaks above $2.85.
The newcomers are impressed by FEMY's multiple major breakthroughs in female health, which they believe are worth a significant amount of money, and are considering adding to their positions at sub-$3 levels, expecting it to explode later on.

Generated by AI

-- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care w

14d agoYahoo Finance

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

20d agoYahoo Finance

Femasys partners with UNC Health for fertility services

1mo agoInvesting.com

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to

1mo agoYahoo Finance

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology. Femasys Inc. (NASDAQ:FEMY) announced the regulatory milestone for its investigational contraceptive device. Office-Based Alternative To Surgical Sterilization FemBloc represents a first-of-its-kind permanent birth control option designed specifically for delivery within a standard OB/GYN office setting. During the p

1mo agoYahoo Finance

Why Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY)

1mo agoBenzinga

Also Discussed

Investors talking about FEMY also mention

#	Name	Attention
1	MultiSensor AI Holdings Inc.MSAI	0%0
2	Dragonfly Energy Holdings Corp.DFLI	0%0
3	BNOX - Bionomics Limited	——
4	AXLA - Axcella Health Inc.	——
5	Tempest Therapeutics Inc.TPST	0%+0
6	Avalo Therapeutics, Inc.AVTX	0%0
7	ICCT - iCoreConnect Inc.	——
8	ParaZero Technologies Ltd.PRZO	0%+0
9	Cardio Diagnostics Holdings, Inc.CDIO	0%0
10	AWIN - AERWINS Technologies Inc.	——

Femasys Inc.

Healthcare
Medical Instruments & Supplies

Femasys Inc. is a biomedical company focused on women’s reproductive health. The company develops and commercializes accessible, minimally invasive, in-office therapeutic and diagnostic products designed to address unmet needs in fertility care, birth control, and gynecologic testing. Its portfolio includes FemVue for fallopian tube assessment, FemCath for selective tube evaluation, FemCerv for endocervical tissue sampling, FemBloc for non-surgical permanent birth control, and FemaSeed for assisted insemination. Femasys also offers related products and technologies used by physicians and women’s healthcare providers in office-based settings. Headquartered in Suwanee, Georgia, Femasys serves both U.S. and international markets with a focus on improving reproductive healthcare delivery.

Website

Location

3950 Johns Creek Court

Suwanee, GA, 30024

United States

Social

What share of all stock conversation is about FEMY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% -0.01	0% 0

Aug 28

Femasys Inc. (FEMY) has partnered with UNC, and its undervalued market capitalization can support a price of $10+.
The company's regulatory milestone for its investigational birth control technology has led to a stock rally, with potential for 500% upside.
FEMY's low volume and price movement are notable, despite the market's fickle nature and potential for further dips or a significant run.

Generated by AI

Sentiment

Of the messages about FEMY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	85.71% +2.11	85.62% -3
Bearish	—	100% new	14.29% -2.11	14.38% +3

Bullish· Aug 19

FEMY has secured $30M in institutional financing, which has taken a significant strategic position in the company, and has also received millions of warrants with strikes at $2.95.
FEMY has made significant progress with the FDA, agreeing to a modular PMA pathway for FemBloc, and has already received approval for marketing in Europe and select international markets.
FEMY's recent news and financing in place have attracted key institutional investors, including Nantahala Capital, which has invested ~$12M at $3.20/share, and received millions of warrants.

Bearish· Aug 19

The company's FDA approval news may not lead to immediate financial improvement and could be used for pump and dump campaigns.
Many investors are expecting a significant price drop, with some predicting a 30% decline from the current level.
The asset is considered a "piece of trash" and "diarrhea" by some investors, with one predicting it will go to $2.86 and another stating it will be a 100% loss.

Generated by AI

Topics

Of the messages about FEMY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	16.56%
Technical Analysis	—	—	0%	17.22%
Analysts	—	—	0%	31.96%
Macro	—	—	0%	29.57%
Controversies	—	—	0%	0%
Earnings	—	—	0%	4.69%

Earnings· Nov 16

FEMY fell despite beating estimates, potentially due to unclear EPS release date and low trading volume.
DFLI, another stock that missed estimates, surged instead, possibly due to its own characteristics and lower short interest.
FEMY and DFLI are both being suppressed by significant short interest and have not yet achieved full profitability.

Announcements· Nov 7

Femasys Inc. (FEMY) has filed an 8-K announcing a $12 million private placement of senior secured convertible notes and warrants.
The private placement includes personal investments by the CEO, CFO, and a board member, indicating their confidence in the company's growth prospects.
The funds raised will be used to pay off previous debt and fund operations, with the lead investor taking a board seat to signal long-term commitment and support for the company's expansion plans.

Technical Analysis· Oct 17

$FEMY is in a consolidation phase just below its 21-day EMA and needs to break above 1.65 to start a new momentum.
The stock has been trending sideways, with STO/RSI momentum oscillators twitching just above the oversold zone, and has a potential reversal signal due to its accumulation level.
$FEMY has formed a bullish deep bat formation from 1.31, indicating a strong buy signal, and has broken out of a down-trending channel, with a potential gap up above 1.55-1.60.

Generated by AI

Community

Of the messages about FEMY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	63.64%	37.34%
Newcomers	0%	0%	36.36%	62.66%

Regulars· Aug 19

Femasys has received $30M in institutional financing, with Nantahala taking a significant strategic position, and the FDA agreeing to a modular PMA pathway for FemBloc, potentially shortening the time to approval.
The FDA's agreement to a modular PMA pathway is a positive signal, and Femasys already has FemBloc approved for marketing in Europe and select international markets.
Femasys has the potential to become a non-surgical alternative to hysterectomies, with FemBloc already approved in Europe and New Zealand, and the company has a significant amount of cash on hand.

Newcomers· Aug 19

The newcomers are primarily focused on the potential for FEMY to increase in value, with some predicting it will reach $4 today and others anticipating a significant surge in value, potentially reaching $10-20 billion.
The newcomers are also focused on the potential for FEMY to break out above $3.15, with some already buying in at $3.00 and others expecting a rapid increase in value if it breaks above $2.85.
The newcomers are impressed by FEMY's multiple major breakthroughs in female health, which they believe are worth a significant amount of money, and are considering adding to their positions at sub-$3 levels, expecting it to explode later on.

Generated by AI

Femasys

Social

Aug 28

Bullish· Aug 19

Bearish· Aug 19

Earnings· Nov 16

Announcements· Nov 7

Technical Analysis· Oct 17

Regulars· Aug 19

Newcomers· Aug 19

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys partners with UNC Health for fertility services

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Why Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY)

Also Discussed

Femasys Inc.

Company Information

Location

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys partners with UNC Health for fertility services

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Why Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY)

Also Discussed

Social

Aug 28

Bullish· Aug 19

Bearish· Aug 19

Earnings· Nov 16

Announcements· Nov 7

Technical Analysis· Oct 17

Regulars· Aug 19

Newcomers· Aug 19